S&P 500
7,804.22
-3.02
-0.04%
Dow
51,717.77
-132.78
-0.26%
Nasdaq
27,189.93
-55.97
-0.21%
NYSE Composite
24,003.97
+64.87
+0.27%
Russell 2000
2,786.47
-20.51
-0.73%
VIX
15.47
+0.63
+4.25%
SLDB · Solid Biosciences Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Solid Biosciences Inc (SLDB)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$5.88
-0.82
(-12.18%)
● Market open
DAY'S RANGE
$5.88
$5.70
$6.59
52-WEEK RANGE
$5.88
$3.79
$11.45
What's happening
- SLDB is down 12.18% today, trading at $5.88. — Live quote
- Volume today (150,806) is well below its 3-month average of 1,499,550. (Finnhub fundamentals)
- Reports earnings on 2026-11-02, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.38 actual vs. $-0.48 estimated (+20.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 10
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SLDB
+21.81%
vs S&P 500
+7.64%
1-YEAR RETURN
SLDB
+7.34%
vs S&P 500
-8.66%
6-MONTH RETURN
SLDB
-11.24%
3-MONTH RETURN
SLDB
-34.07%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.38
Est. $-0.48
BEAT +20.4%
2026-04-26 (Q1 2026)
$-0.52
Est. $-0.44
MISS -17.6%
2026-01-26 (Q4 2025)
$-0.53
Est. $-0.53
MISS -0.2%
2025-10-26 (Q3 2025)
$-0.48
Est. $-0.45
MISS -7.3%
Valuation Measures & Ratios
Enterprise Value4$565.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)49.01
Price / Book72.63
EV4 / Revenue38.23
EV4 / EBITDA—
Profit Margin-588.30%
Operating Margin-591.14%
Return on Equity (ROE8)-72.28%
Return on Assets (ROA9)-61.37%
Avg Volume (3M)1,499,550
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short12,726,346
Change from Prior Settlement-25.60%
% of Float—
Days to Cover (Short Ratio)7.69
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +7.3%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -588.3%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-06; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SLDB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$57.4M | -$57.3M | -$48.1M | -$41.7M | -$40.1M | -$35.2M | -$27.8M | -$26.9M |
| Net income | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-0.38 | $-0.52 | $-0.48 | $-0.42 | $-0.59 | $-0.79 | $-0.61 | $-0.64 |
| EPS (basic) | $-0.38 | $-0.52 | $-0.48 | $-0.42 | $-0.59 | $-0.79 | $-0.61 | $-0.64 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $420.6M | $422.9M | $232.5M | $273.9M | $308.3M | $343.9M | $188.7M | $211.8M |
| Total liabilities | $46.5M | $48.8M | $52.5M | $56.0M | $50.0M | $49.4M | $51.4M | $44.8M |
| Stockholders' equity | $374.1M | $374.1M | $180.0M | $217.9M | $258.3M | $294.5M | $137.2M | $167.0M |
| Total current assets | $395.1M | $396.8M | $205.5M | $244.9M | $278.6M | $313.4M | $157.3M | $179.5M |
| Total current liabilities | $28.6M | $30.3M | $33.5M | $36.3M | $29.8M | $28.8M | $30.3M | $22.9M |
| Cash & equivalents | $159.4M | $297.1M | $59.9M | $61.4M | $138.9M | $210.6M | $80.2M | $64.4M |
| Property, plant & equipment | $4.0M | $3.9M | $4.2M | $4.4M | $4.3M | $4.5M | $4.7M | $5.1M |
| Other non-current assets | $138.0K | $183.0K | $223.0K | $247.0K | $278.0K | $319.0K | $366.0K | $475.0K |
| Accounts payable | $4.4M | $5.6M | $3.2M | $8.4M | $4.7M | $6.4M | $4.2M | $3.5M |
| Accrued liabilities | $17.8M | $19.2M | $18.9M | $19.1M | $16.5M | $14.6M | $19.9M | $13.2M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $105.0K | $98.0K | $79.0K | $78.0K | $78.0K | $77.0K | $40.0K | $39.0K |
| Retained earnings | -$1.07B | -$1.01B | -$957.8M | -$908.0M | -$862.2M | -$822.7M | -$783.5M | -$740.9M |
| Accumulated other comprehensive income (loss) | -$113.0K | -$13.0K | $52.0K | $48.0K | -$38.0K | $2.0K | $47.0K | $116.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$52.6M | -$47.2M | -$53.6M | -$33.5M | -$37.4M | -$31.9M | -$29.6M | -$23.7M |
| Investing cash flow | -$133.6M | $44.8M | $47.0M | -$45.3M | -$32.7M | -$27.5M | $38.6M | -$11.0M |
| Financing cash flow | $48.5M | $239.0M | $5.1M | $1.2M | -$1.6M | $189.7M | $6.9M | $3.3M |
| Free cash flow | -$52.7M | -$47.4M | -$54.1M | -$33.6M | -$37.8M | -$32.0M | -$29.8M | -$23.7M |
| Capital expenditures | $150.0K | $165.0K | $565.0K | $85.0K | $377.0K | $126.0K | $204.0K | $15.0K |
| Share-based compensation | $5.6M | $5.2M | $6.5M | $3.9M | $3.1M | $3.3M | $3.8M | $3.0M |
| Change in accounts payable | -$1.2M | $2.3M | -$5.3M | $3.7M | $6.0K | $461.0K | $815.0K | $918.0K |
| Purchases of investments | $151.9M | $83.5M | $23.9M | $83.2M | $63.4M | $65.3M | $15.3M | $85.5M |
| Other investing activities | $0 | — | — | $0 | -$85.0K | $0 | — | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $8.1M | $13.6M |
| Operating income | -$179.2M | -$129.7M | -$104.3M | -$106.5M | -$72.3M |
| Net income | — | — | — | — | — |
| EPS (diluted) | $-1.99 | $-3.06 | $-4.83 | $-10.10 | $-10.14 |
| EPS (basic) | $-1.99 | $-3.06 | $-4.83 | $-10.10 | $-10.14 |
| Operating margin | — | — | — | -$1.3K | -$530 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $232.5M | $188.7M | $164.9M | $260.3M | $232.4M |
| Total liabilities | $52.5M | $51.4M | $38.5M | $48.6M | $24.2M |
| Stockholders' equity | $180.0M | $137.2M | $126.5M | $211.7M | $208.2M |
| Total current assets | $205.5M | $157.3M | $129.7M | $219.6M | $222.6M |
| Total current liabilities | $33.5M | $30.3M | $14.5M | $22.5M | $23.6M |
| Cash & equivalents | $59.9M | $80.2M | $74.0M | $155.4M | $119.1M |
| Property, plant & equipment | $4.2M | $4.7M | $6.6M | $9.7M | $6.5M |
| Other non-current assets | $223.0K | $366.0K | $209.0K | $175.0K | $94.0K |
| Accounts payable | $3.2M | $4.2M | $2.0M | $3.2M | $4.5M |
| Accrued liabilities | $18.9M | $19.9M | $10.2M | $16.7M | $9.5M |
| Deferred revenue (current) | — | — | — | — | $8.1M |
| Other current liabilities | — | — | $24.0K | $14.0K | $35.0K |
| Other non-current liabilities | — | — | — | $96.0K | — |
| Common stock & paid-in capital | $79.0K | $40.0K | $20.0K | $20.0K | $7.0K |
| Retained earnings | -$957.8M | -$783.5M | -$658.8M | -$562.7M | -$476.8M |
| Accumulated other comprehensive income (loss) | $52.0K | $47.0K | $15.0K | -$68.0K | -$45.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$156.3M | -$100.0M | -$94.2M | -$98.0M | -$77.8M |
| Investing cash flow | -$58.5M | -$16.1M | $9.7M | $59.2M | -$91.1M |
| Financing cash flow | $194.4M | $122.4M | $3.1M | $74.8M | $135.0M |
| Free cash flow | -$157.4M | -$100.7M | -$95.7M | -$101.0M | -$79.0M |
| Capital expenditures | $1.2M | $654.0K | $1.5M | $3.0M | $1.3M |
| Share-based compensation | $16.9M | $10.5M | $7.6M | $7.5M | $13.4M |
| Change in accounts payable | -$1.1M | $2.2M | -$764.0K | -$5.2M | $1.2M |
| Purchases of investments | $235.9M | $204.3M | $117.4M | $182.8M | $141.2M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SLDB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers73.5%
Shares Outstanding143,688,701
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 12,036,126 | $120.2M | 8.38% | +28.9% | 2026-08-14 |
| PERCEPTIVE ADVISORS LLC | 11,906,646 | $118.9M | 8.29% | +0.0% | 2026-08-14 |
| Bain Capital Life Sciences Investors, LLC | 9,808,819 | $98.0M | 6.83% | +0.0% | 2026-08-14 |
| Siren, L.L.C. | 7,690,405 | $76.8M | 5.35% | +0.0% | 2026-08-13 |
| BlackRock, Inc. | 6,934,248 | $69.3M | 4.83% | +39.8% | 2026-08-07 |
| FMR LLC | 6,875,957 | $68.7M | 4.79% | +90.7% | 2026-08-13 |
| ARMISTICE CAPITAL, LLC | 4,278,000 | $42.7M | 2.98% | +33.7% | 2026-08-14 |
| State Street Corp | 4,175,365 | $41.7M | 2.91% | +271.0% | 2026-08-07 |
| Jupiter Topco LLC | 4,043,605 | $40.4M | 2.81% | +0.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,009,922 | $40.1M | 2.79% | +0.0% | 2026-06-30 |
| RTW INVESTMENTS, LP | 3,892,926 | $38.9M | 2.71% | +0.0% | 2026-08-14 |
| Deep Track Capital, LP | 3,565,062 | $35.6M | 2.48% | +0.0% | 2026-08-14 |
| Franklin Templeton Inc | 3,440,708 | $34.4M | 2.39% | +56.9% | 2026-08-04 |
| CITADEL ADVISORS LLC | 2,815,122 | $28.1M | 1.96% | +8.4% | 2026-08-14 |
| Alyeska Investment Group, L.P. | 2,280,484 | $22.8M | 1.59% | +0.0% | 2026-08-14 |
| Ameriprise Financial Inc | 2,225,783 | $22.2M | 1.55% | -8.7% | 2026-08-14 |
| Vestal Point Capital, LP | 2,160,000 | $21.6M | 1.50% | -56.8% | 2026-08-14 |
| Redmile Group, LLC | 1,948,695 | $19.5M | 1.36% | -3.1% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,940,824 | $19.4M | 1.35% | +49.8% | 2026-08-12 |
| Goldman Sachs Group Inc | 1,602,917 | $16.0M | 1.12% | +71.3% | 2026-08-14 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,506,506 | $15.0M | 1.05% | -14.2% | 2026-08-14 |
| DIMENSIONAL FUND ADVISORS LP | 1,266,290 | $12.6M | 0.88% | +32.4% | 2026-08-11 |
| BLAIR WILLIAM & CO/IL | 756,277 | $7.6M | 0.53% | +16.1% | 2026-08-11 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 748,589 | $7.5M | 0.52% | +0.0% | 2026-06-30 |
| Woodline Partners LP | 674,076 | $6.7M | 0.47% | +36.2% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-13 to 2026-10-02
Recent transactions
- Most recent: SMITH IAN F (Reporting person) — Option exercise of 3,440 shares on 2026-10-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| SMITH IAN F | Reporting person | Option exercise | 2026-10-02 | 3,440 |
| Cumbo Alexander | President and CEO | Open market sale | 2026-02-18 | 16,644 |
| Hanrahan Jessie | Chief Regulatory Officer | Open market sale | 2026-02-18 | 4,134 |
| Ganot Ilan | Reporting person | Open market sale | 2026-02-18 | 2,658 |
| Herzich Paul | Chief Technology Officer | Open market sale | 2026-02-18 | 3,616 |
| Howton David T | Chief Operating Officer | Open market sale | 2026-02-18 | 7,469 |
| Brooks Gabriel | Chief Medical Officer | Open market sale | 2026-02-18 | 0 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-02 | SMITH IAN F | Reporting person | Option exercise | 3,440 | — |
| 2026-07-02 | SMITH IAN F | Reporting person | Option exercise | 3,440 | — |
| 2026-04-02 | SMITH IAN F | Reporting person | Option exercise | 3,441 | — |
| 2026-02-18 | Cumbo Alexander | President and CEO | Open market sale | 16,644 | $5.82 |
| 2026-02-18 | Hanrahan Jessie | Chief Regulatory Officer | Open market sale | 4,134 | $5.82 |
| 2026-02-18 | Ganot Ilan | Reporting person | Open market sale | 2,658 | $5.82 |
| 2026-02-18 | Herzich Paul | Chief Technology Officer | Open market sale | 3,616 | $5.82 |
| 2026-02-18 | Howton David T | Chief Operating Officer | Open market sale | 7,469 | $5.82 |
| 2026-02-18 | Brooks Gabriel | Chief Medical Officer | Open market sale | 0 | $5.82 |
| 2026-02-13 | Cumbo Alexander | President and CEO | Option exercise | 30,031 | — |
| 2026-02-13 | Hanrahan Jessie | Chief Regulatory Officer | Option exercise | 8,125 | — |
| 2026-02-13 | Ganot Ilan | Reporting person | Option exercise | 4,861 | — |
| 2026-02-13 | Herzich Paul | Chief Technology Officer | Option exercise | 7,187 | — |
| 2026-02-13 | Howton David T | Chief Operating Officer | Option exercise | 14,687 | — |
| 2026-02-13 | Brooks Gabriel | Chief Medical Officer | Option exercise | 10,937 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-13 18:46 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-06 | 4 | 2026-10-02 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-02 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-10 | View on SEC.gov → |
Recent news
Headlines about SLDB (Solid Biosciences Inc.). Links open the publisher — we don’t host full articles.
-
SLDB Mar 2027 7.000 call (SLDB270319C00007000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-13 -
Form 4 Solid Biosciences LLC For: 11 October By Investing.com
Investing.com Nigeria · 2026-10-11 -
Solid Biosciences Inc. (SLDB) Stock Price | Live Quotes & Charts | NASDAQ
StocksToTrade · 2026-10-10 -
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 2026-10-09 -
What Explains the 5.72% Premarket Gain for Solid Biosciences (NASDAQ:SLDB)?
Kalkine · 2026-10-09 -
The Technical Signals Behind (SLDB) That Institutions Follow
Stock Traders Daily · 2026-10-08 -
Solid Biosciences stock fell 1.98 percent after Q2 EPS beat consensus - ad-hoc-news.de
ad-hoc-news.de · 2026-10-07 -
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo · 2026-10-01
No headlines in this category right now — try “All”.